



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 08<sup>th</sup> November, 2023

To

The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Subject: Outcome of Board Meeting and Financial Results for the second quarter and half year ended 30<sup>th</sup> September, 2023.**

With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e., 08<sup>th</sup> November, 2023, have *inter- alia*, transacted the following item(s) of the Agenda:

- ❖ Approved the standalone and consolidated un-audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2023 and a copy of the same is enclosed along with Limited Review Report of the Statutory Auditors of the Company.

The meeting of Board of Directors commenced at 10.00 a.m. and concluded at about 12.45 p.m.

Please take the above intimation on your records.

Thanking you

Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary**

Encl: as above

**SMS PHARMACEUTICALS LIMITED**

(CIN : L24239TG1987PLC008066)

Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-35359999 / 2525 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

**Statement of Standalone Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2023**

(Rs. In Lakhs)


S.No	Particulars	Quarter Ended			Half Year ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	16,664.35	13,533.94	15,943.30	30,198.29	22,382.16	52,205.14
2	Other Income	81.03	51.29	61.35	132.32	141.49	491.38
3	<b>Total Revenue</b>	<b>16,745.38</b>	<b>13,585.23</b>	<b>16,004.65</b>	<b>30,330.61</b>	<b>22,523.65</b>	<b>52,696.52</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	10,359.32	9,124.75	8,768.29	19,484.07	14,841.42	29,952.40
	(b) Changes in Inventories	(578.08)	(1,722.28)	2,820.23	(2,300.37)	309.44	3,608.44
	(c) Manufacturing Expenses	1,869.01	1,337.98	1,236.02	3,207.00	2,416.90	5,369.08
	(d) Employee Benefits Expense	1,364.58	1,355.40	1,186.63	2,719.98	2,340.68	5,007.97
	(e) Finance Cost	557.22	632.27	524.31	1,189.49	1,009.31	2,191.33
	(f) Depreciation and Amortization Expense	789.96	769.12	809.21	1,559.09	1,602.55	3,212.54
	(g) Other Expenses	867.36	772.32	570.37	1,639.68	1,154.50	2,799.80
	<b>Total Expenses - (a to g)</b>	<b>15,229.37</b>	<b>12,269.56</b>	<b>15,915.06</b>	<b>27,498.94</b>	<b>23,674.80</b>	<b>52,141.56</b>
5	<b>Profit Before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>1,516.01</b>	<b>1,315.67</b>	<b>89.59</b>	<b>2,831.67</b>	<b>(1,151.15)</b>	<b>554.96</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit Before Extraordinary Items and Tax (5-6)</b>	<b>1,516.01</b>	<b>1,315.67</b>	<b>89.59</b>	<b>2,831.67</b>	<b>(1,151.15)</b>	<b>554.96</b>
8	Extraordinary Items	-	-	-	-	-	-
9	<b>Profit before Tax (7-8)</b>	<b>1,516.01</b>	<b>1,315.67</b>	<b>89.59</b>	<b>2,831.67</b>	<b>(1,151.15)</b>	<b>554.96</b>
10	Tax Expenses						
	(a) Current Tax relating to Current Period	310.00	340.00	-	650.00	-	5.50
	(b) Current Tax relating to Earlier Period	-	-	-	-	-	(5.92)
	(c) Deferred Tax	1.27	47.39	10.81	48.65	(249.39)	146.92
		<b>311.27</b>	<b>387.39</b>	<b>10.81</b>	<b>698.65</b>	<b>(249.39)</b>	<b>146.50</b>
11	<b>Net Profit / (Loss) for the Period (9-10)</b>	<b>1,204.74</b>	<b>928.28</b>	<b>78.78</b>	<b>2,133.02</b>	<b>(901.76)</b>	<b>408.46</b>
12	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(8.23)	(7.54)	1.59	(15.77)	3.03	(27.43)
	Income Tax effect on the above	2.07	1.90	(0.40)	3.97	(0.76)	6.90
		<b>(6.16)</b>	<b>(5.64)</b>	<b>1.19</b>	<b>(11.80)</b>	<b>2.27</b>	<b>(20.53)</b>
13	<b>Total Comprehensive Income for the period (11+12)</b>	<b>1,198.58</b>	<b>922.64</b>	<b>79.97</b>	<b>2,121.22</b>	<b>(899.49)</b>	<b>387.93</b>
14	Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised)	1.42	1.10	0.09	2.52	(1.07)	0.48
15	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						48,663.47



**Standalone Un-Audited Statement of Assets and Liabilities as at 30th September, 2023**

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		30.09.2023 (Unaudited)	31.03.2023 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	40,410.24	40,949.96
	(b) Capital Work-in-Progress	4,286.10	3,319.05
	(c) Right-of-use Assets	71.72	105.23
	(d) Intangible Assets	169.74	146.56
	(e) Financial Assets:		
	(i) Investments	4,509.67	4,509.67
	(ii) Bank Balances	253.64	253.61
	(iii) Other Financial Assets	512.57	508.50
	(f) Other Non-Current Assets	942.35	561.04
	<b>Sub Total :Non-Current Assets</b>	<b>51,156.03</b>	<b>50,353.62</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	27,744.13	22,349.94
	(b) Financial Assets		
	(i) Trade Receivables	15,438.82	14,834.62
	(ii) Cash and Cash Equivalents	3,283.27	737.78
	(iii) Bank Balances (Other than (ii) above)	9.18	9.18
	(iv) Other Financial Assets	563.62	660.12
	(c) Other Current Assets	2,459.56	1,896.97
	(d) Current Tax Asset (Net)	534.27	576.25
	<b>Sub Total : Current Assets</b>	<b>50,032.85</b>	<b>41,064.86</b>
	<b>TOTAL ASSETS</b>	<b>1,01,188.88</b>	<b>91,418.48</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	846.52	846.52
	(b) Other Equity	50,530.74	48,663.47
	<b>Sub-Total -Shareholders' funds</b>	<b>51,377.26</b>	<b>49,509.99</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	11,372.24	12,113.33
	(ii) Lease Liabilities	8.70	61.36
	(b) Provisions	136.62	140.45
	(c) Deferred Tax Liabilities (net)	4,150.65	4,102.00
	<b>Sub-Total -Non-Current Liabilities</b>	<b>15,668.21</b>	<b>16,417.14</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	16,189.40	13,138.01
	(ii) Lease Liabilities	98.18	93.99
	(ii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	27.10	68.93
	(b) Dues to Creditors Otherthan Micro & Small Enterprises	15,892.66	10,674.04
	(iii) Other Financial Liabilities	1,336.62	1,122.32
	(b) Provisions	101.03	104.20
	(c) Other Current Liabilities	498.42	289.86
	<b>Sub-Total - Current Liabilities</b>	<b>34,143.41</b>	<b>25,491.35</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,01,188.88</b>	<b>91,418.48</b>



SMS Pharmaceuticals Limited

Standalone Un-Audited Statement of Cash Flow for the Half Year Ended 30th September, 2023

S No	Particulars	For the Half Year ended 30th September, 2023	For the Year ended 31st March, 2023
A	Cash Flow from Operating Activities		
	Profit Before Tax	2,831.67	554.96
	Adjustments for:		
	Depreciation and Amortisation Expense	1,559.09	3,212.54
	Interest Income	(7.29)	(14.31)
	Interest on lease liability	7.04	22.30
	Interest on Borrowings	1,124.23	2,070.46
	Provision for Employee Benefits	(18.80)	(34.14)
	Amortisation of Transaction Cost on Borrowings	9.10	16.69
	Profit on Sale of Assets	(2.28)	(1.75)
	Loss on Sale of Assets	-	7.19
	Operating Profit before Working Capital Changes	5,502.76	5,833.94
	Change in Operating Assets and Liabilities		
	(Increase)/Decrease in Trade Receivables	(604.20)	(9,982.69)
	(Increase)/Decrease in Inventories	(5,394.19)	2,759.81
	(Increase)/Decrease in Other Non Current Financial Assets	(4.07)	(6.25)
	(Increase)/Decrease in Other Non Current Asset	(381.31)	(130.98)
	(Increase)/Decrease in Other Current Financial Assets	103.41	(378.45)
	(Increase)/Decrease in Other Current Assets	(562.59)	468.17
	(Increase)/Decrease in Prepaid Taxes	(28.02)	329.07
	Increase/(Decrease) in Trade Payables	5,176.80	4,029.02
	Increase/(Decrease) in Other Current Financial Liabilities	(62.17)	-
	Increase/(Decrease) in Other Current Liabilities	186.63	(216.63)
		(1,569.71)	(3,128.94)
	Cash generated from Operations	3,933.05	2,705.00
	Income Taxes Paid	(580.00)	(460.00)
	Net Cash Inflow from Operating Activities "A"	3,353.05	2,245.00
B	Cash flows from Investing Activities		
	Purchase of Property, Plant and Equipment	(1,989.71)	(2,992.07)
	Sale of Property, Plant and Equipment	6.50	26.33
	Investment in LLP	-	(9.80)
	Margin Money Deposits	-	(8.88)
	Interest Received on Margin Money Deposit	-	15.81
	Net Cash Outflow from Investing Activities "B"	(1,983.21)	(2,968.61)
C	Cash Flows from Financing Activities		
	Proceeds from Long Term Borrowings	1,558.63	941.37
	Repayment of Long Term Borrowings	(1,769.58)	(4,305.79)
	Proceeds from Short Term Borrowings	2,512.25	2,587.71
	Interest paid on Borrowings	(1,074.58)	(2,092.76)
	Repayment of Lease Liability	(51.07)	(73.46)
	Dividend Paid to Company's Shareholders	-	(253.96)
	Net Cash Inflow (Outflow) from Financing Activities "C"	1,175.65	(3,196.89)
	Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)	2,545.49	(3,920.50)
	Cash and Cash Equivalents at the Beginning of the Financial Year	737.78	4,658.28
	Cash and Cash Equivalents at End of the Half Year	3,283.27	737.78



**Notes:**

- 1 The above standalone un-audited financial results for the quarter ended September 30, 2023 have been reviewed by the Audit Committee on November 07, 2023 and approved by the Board of Directors at their meeting held on November 08, 2023. The statutory auditors of the Company have carried out a limited review on standalone financial results for the quarter ended September 30, 2023 and expressed an unmodified conclusion thereon.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 As approved by the Members of the company at the 35th Annual General Meeting held on September 30, 2023, the company has disbursed on October 04, 2023 a dividend of Re.0.30 per equity share of Re.1 each for the year ended March 31, 2023, aggregating to Rs.253.96 lakhs (Including an amount of Rs 23.67 lakhs towards Tax Deducted at Source).
- 5 Figures for the previous period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 08-11-2023



**For SMS Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

**Ramesh Babu Potluri**  
**Chairman and Managing Director**  
**DIN : 00166381**



**Independent Auditor's Review Report Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors  
SMS Pharmaceuticals Limited  
Hyderabad.

**Report on the Review of Standalone Financial Results**

We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter ended September 30, 2023 and year to date from April 01, 2023 to September 30, 2023. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: November 08, 2023

**For Suryanarayana & Suresh,**  
Chartered Accountants  
Reg. No.006631S

*V Nagendra Rao*  
V Nagendra Rao  
Partner  
M.No. 227679



UDIN:23227679BGSHEFW5506

## SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)

Regd. Office: Plot No.72, H.No.8-2-334/3&amp;4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-35359999 / 2525 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com


Statement of Consolidated Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2023

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	16,664.35	13,533.94	15,943.30	30,198.29	22,382.16	52,205.14
2	Other Income	81.03	51.29	61.35	132.32	141.49	491.38
3	Total Revenue	16,745.38	13,585.23	16,004.65	30,330.61	22,523.65	52,696.52
4	Expenses						
	(a) Cost of Materials Consumed	10,359.39	9,172.15	8,773.93	19,531.53	14,885.51	29,972.45
	(b) Changes in Inventories	(578.08)	(1,722.28)	2,820.23	(2,300.37)	309.44	3,608.44
	(c) Manufacturing Expenses	1,869.01	1,337.98	1,236.02	3,207.00	2,416.90	5,369.08
	(d) Employee Benefits Expense	1,364.58	1,355.40	1,186.63	2,719.98	2,340.68	5,007.97
	(e) Finance Cost	557.22	632.27	524.31	1,189.49	1,009.31	2,191.33
	(f) Depreciation and Amortization Expense	789.96	769.12	809.21	1,559.09	1,602.55	3,212.54
	(g) Other Expenses	867.36	772.32	570.37	1,639.68	1,154.50	2,799.80
	Total Expenses - (a to g)	15,229.44	12,316.96	15,920.70	27,546.40	23,718.89	52,161.61
5	Profit Before Exceptional and Extraordinary Items and Tax (3-4)	1,515.94	1,268.27	83.95	2,784.21	(1,195.24)	534.91
6	Exceptional items	-	-	-	-	-	-
7	Profit Before Extraordinary Items and Tax (5-6)	1,515.94	1,268.27	83.95	2,784.21	(1,195.24)	534.91
8	Extraordinary Items	-	-	-	-	-	-
9	Profit before Tax (7-8)	1,515.94	1,268.27	83.95	2,784.21	(1,195.24)	534.91
10	Tax Expenses						
	(a) Current Tax relating to Current Period	310.00	340.00	-	650.00	-	5.50
	(b) Current Tax relating to Earlier Period	-	-	-	-	-	(5.92)
	(c) Deferred Tax	1.26	47.39	10.81	48.65	(249.39)	146.92
		311.26	387.39	10.81	698.65	(249.39)	146.50
11	Net Profit / (Loss) for the Period (9-10)	1,204.68	880.88	73.14	2,085.56	(945.85)	388.41
	Share of Profit/(Loss) in associate companies	(32.17)	53.28	(273.98)	21.11	(531.67)	(1,094.34)
		1,172.51	934.16	(200.84)	2,106.67	(1,477.52)	(705.93)
12	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:						
	Income Tax effect on the above	(8.23)	(7.54)	1.59	(15.77)	3.03	(27.43)
	Share of Other Comprehensive Income in Associates	2.07	1.90	(0.40)	3.97	(0.76)	6.90
	Share of Income Tax effect on the above in Associates	1.39	1.37	1.39	2.75	2.77	5.51
	Other Comprehensive Income/(Loss) after Tax for the Period/Year	(0.35)	(0.36)	(0.36)	(0.71)	(0.72)	(1.43)
		(5.12)	(4.64)	2.22	(9.76)	4.32	(16.45)
13	Total Comprehensive Income for the period (11+12)	1,167.39	929.52	(198.62)	2,096.91	(1,473.20)	(722.38)
14	Earning Per Equity Share of Re.1/- each						
	Basic / Diluted (not annualised)	1.39	1.10	(0.24)	2.49	(1.75)	(0.83)
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						45,206.00



Sr. No.	Particulars	As at	As at
		30.09.2023 (Unaudited)	31.03.2023 (Audited)
<b>A</b>	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	40,410.24	40,949.96
	(b) Capital Work-in-Progress	4,286.10	3,319.05
	(c) Right-of-use Assets	71.72	105.23
	(d) Intangible Assets	169.74	146.56
	(e) Financial Assets:		
	(i) Investments	1,027.88	1,052.20
	(ii) Bank Balances	253.64	253.61
	(iii) Other Financial Assets	512.57	508.50
	(f) Other Non-Current Assets	942.35	561.04
	<b>Sub Total :Non-Current Assets</b>	<b>47,674.24</b>	<b>46,896.15</b>
2	<b>Current Assets</b>		
	(a) Inventories	27,744.13	22,349.94
	(b) Financial Assets		
	(i) Trade Receivables	15,438.82	14,834.62
	(ii) Cash and Cash Equivalents	3,283.27	737.78
	(iii) Bank Balances (Other than (ii) above)	9.18	9.18
	(iv) Other Financial Assets	563.62	660.12
	(c) Other Current Assets	2,459.56	1,896.97
	(d) Current Tax Asset (Net)	534.27	576.25
	<b>Sub Total : Current Assets</b>	<b>50,032.85</b>	<b>41,064.86</b>
	<b>TOTAL ASSETS</b>	<b>97,707.09</b>	<b>87,961.01</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity:</b>		
	(a) Equity Share Capital	846.52	846.52
	(b) Other Equity	47,048.95	45,206.00
	<b>Sub-Total -Shareholders' funds</b>	<b>47,895.47</b>	<b>46,052.52</b>
	<b>Liabilities:</b>		
2	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	11,372.24	12,113.33
	(ii) Lease Liabilities	8.70	61.36
	(b) Provisions	136.62	140.45
	(c) Deferred Tax Liabilities (net)	4,150.65	4,102.00
	<b>Sub-Total -Non-Current Liabilities</b>	<b>15,668.21</b>	<b>16,417.14</b>
3	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	16,189.40	13,138.01
	(ii) Lease Liabilities	98.18	93.99
	(ii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	27.10	68.93
	(b) Dues to Creditors Otherthan Micro & Small Enterprises	15,892.66	11,245.87
	(iii) Other Financial Liabilities	1,336.62	550.49
	(b) Provisions	101.03	104.20
	(c) Other Current Liabilities	498.42	289.86
	<b>Sub-Total - Current Liabilities</b>	<b>34,143.41</b>	<b>25,491.35</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>97,707.09</b>	<b>87,961.01</b>





SMS Pharmaceuticals Limited

Consolidated Un-Audited Statement of Cash Flow for the Half Year Ended 30th September, 2023

S No	Particulars	For the Half Year ended 30th September, 2023	For the Year ended 31st March, 2023
<b>A</b>	<b>Cash Flow from Operating Activities</b>		
	Profit Before Tax	2,784.21	534.91
	Adjustments for:	-	
	Depreciation and Amortisation Expense	1,559.09	3,212.54
	Interest Income	(7.29)	(14.31)
	Interest on lease liability	7.04	22.30
	Interest on Borrowings	1,124.23	2,070.46
	Provision for Employee Benefits	(18.80)	(34.14)
	Amortisation of Transaction Cost on Borrowings	9.10	16.69
	Profit on Sale of Assets	(2.28)	(1.75)
	Loss on Sale of Assets	-	7.19
	Unrealized Profit in Associate Company Sales	47.46	20.05
	<b>Operating Profit before Working Capital Changes</b>	<b>5,502.76</b>	<b>5,833.94</b>
	<b>Change in Operating Assets and Liabilities</b>		
	(Increase)/Decrease in Trade Receivables	(604.20)	(9,982.69)
	(Increase)/Decrease in Inventories	(5,394.19)	2,759.81
	(Increase)/Decrease in Other Non Current Financial Assets	(4.07)	(6.25)
	(Increase)/Decrease in Other Non Current Asset	(381.31)	(130.98)
	(Increase)/Decrease in Other Current Financial Assets	103.41	(378.46)
	(Increase)/Decrease in Other Current Assets	(562.59)	468.17
	(Increase)/Decrease in Prepaid Taxes	(28.02)	329.07
	Increase/(Decrease) in Trade Payables	5,176.80	4,029.02
	Increase/(Decrease) in Other Financial Liabilities	(62.17)	-
	Increase/(Decrease) in Other Current Liabilities	186.63	(216.63)
		<b>(1,569.71)</b>	<b>(3,128.94)</b>
	<b>Cash generated from Operations</b>	<b>3,933.05</b>	<b>2,705.00</b>
	Income Taxes Paid	(580.00)	(460.00)
	<b>Net Cash Inflow from Operating Activities "A"</b>	<b>3,353.05</b>	<b>2,245.00</b>
<b>B</b>	<b>Cash flows from Investing Activities</b>		
	Purchase of Property, Plant and Equipment	(1,989.71)	(2,992.07)
	Sale of Property, Plant and Equipment	6.50	26.33
	Investment in LLP	-	(9.80)
	Margin Money Deposits	-	(8.88)
	Interest Received on Margin Money Deposit	-	15.81
	<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(1,983.21)</b>	<b>(2,968.61)</b>
<b>C</b>	<b>Cash Flows from Financing Activities</b>		
	Proceeds from Long Term Borrowings	1,558.63	941.37
	Repayment of Long Term Borrowings	(1,769.58)	(4,305.79)
	Proceeds from Short Term Borrowings	2,512.25	2,587.71
	Interest paid on Borrowings	(1,074.58)	(2,092.76)
	Repayment of Lease Liability	(51.07)	(73.46)
	Dividend Paid to Company's Shareholders	-	(253.96)
	<b>Net Cash Inflow (Outflow) from Financing Activities "C"</b>	<b>1,175.65</b>	<b>(3,196.89)</b>
	<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>2,545.49</b>	<b>(3,920.50)</b>
	Cash and Cash Equivalents at the Beginning of the Financial Year	737.78	4,658.28
	<b>Cash and Cash Equivalents at End of the Year</b>	<b>3,283.27</b>	<b>737.78</b>

**Notes:**

- 1 The above un-audited consolidated financial results for the quarter ended September 30, 2023 have been reviewed by the Audit Committee on November 07, 2023 and has been approved by the Board of Directors at its meeting held on November 08, 2023. The statutory auditors of the Company have carried out a limited review on consolidated financial results for the quarter ended September 30, 2023 and expressed an unmodified conclusion thereon.
- 2 These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder("INDAS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3 VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the Company holds 36.55% as on September 30, 2023 in their equity. Accordingly, the results include appropriate share of the results of said Associate . The Company has another Joint venture "Chemo SMS Enterprises SL" in which there were no financial operations during the reporting period.
- 4 Consolidated Financial Statements have been prepared by applying Accounting Standard "Ind AS" 28 "Accounting for Investments in Associates in Consolidated Financial Statements" as applicable under the Companies Act,2013 and applicable rules there under.
- 5 The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 As approved by the Members of the company at the 35th Annual General Meeting held on September 30,2023, the company has disbursed on October 04, 2023 a dividend of Re.0.30 per equity share of Re.1 each for the year ended March 31, 2023, aggregating to Rs.253.96 lakhs (Including an amount of Rs 23.67 lakhs towards Tax Deducted at Source).
- 7 Figures for the previous period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 08-11-2023



**For SMS Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

**Ramesh Babu Potluri**  
**Chairman and Managing Director**  
**DIN : 00166381**



## INDEPENDENT AUDITOR'S REVIEW REPORT

### TO THE BOARD OF DIRECTORS OF SMS PHARMACEUTICALS LIMITED

#### Report on the Review of Consolidated Financial Results

1. We have reviewed the accompanying "Statement of Consolidated Unaudited financial results for the quarter and half year ended September, 2023", the "Statement of Consolidated Unaudited Assets and Liabilities as on September 30, 2023" and the "Statement of Consolidated Unaudited Cash Flows for the half year ended September, 2023" (the "Consolidated Statement") of SMS Pharmaceuticals Ltd (the "holding company), and its associate (the holding company and its associate hereinafter referred to as the "Group"), for the quarter ended September 30, 2023 and the year to date results for the period April 01, 2023 to September 30, 2023. The Consolidated Statement is being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015").
2. This Consolidated Statement, which is the responsibility of the holding company's management and has been approved by the holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Consolidated Statement includes the results of the following associate entity/ joint venture:
  - a) VKT Pharma Private Limited
  - b) Chemo SMS Enterprises SL
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited financial statements/ financial results of associate nameIy VKT Pharma Private Limited which have been reviewed by their auditor whose financial statements / financial results reflect total assets of Rs.21,725.87lakhs as at September 30, 2023 total revenue of Rs.1,426.13 lakhs, total net profit/(loss) after tax of Rs.(88.01) lakhs and total comprehensive income/(loss) of Rs.2.83 lakhs for the quarter ended September 30, 2023.
7. Our conclusion on the Consolidated Statement is not modified in respect of the above matter.

Place: Hyderabad  
Date: November 08, 2023

UDIN:23227679BGSHFX1952

ForSuryanarayana& Suresh.,  
Chartered Accountants  
Reg. No.006631S



V NagendraRao  
Partner  
M. No. 227679

